---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000070"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:45:06.093823+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Halozyme awards CEO $10M performance-based RSUs tied to stock price targets $115-$170

## Summary
- Compensation Committee approved one-time PSU grant for CEO Dr. Helen Torley with $10M target fair value.
- Shares vest based on achieving 20-trading-day average stock price of $115 (50%), $130 (100%), $145 (150%), or $170 (200%) over 4-year performance period.
- Time-based vesting requires continued employment through fourth anniversary; voluntary resignation/retirement forfeits all performance-vested shares.
- Grant intended to retain CEO and incentivize growth and profitability during next stage.

## SEC filing metadata
- accession: 0001159036-25-000070
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000070/0001159036-25-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000070/halo-20251204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000070
- JSON: https://secwatch.observer/filing/0001159036-25-000070.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.